Reuters logo
BRIEF-Galenica says FDA approves supplemental new drug application for Veltassa
2016年11月28日 / 早上6点11分 / 10 个月前

BRIEF-Galenica says FDA approves supplemental new drug application for Veltassa

Nov 28 (Reuters) - Galenica AG :

* FDA approves supplemental new drug application (SNDA) for Veltassa removing boxed warning regarding drug-drug interactions01

* Approval reinforces potential of Veltassa as a key platform of additional growth for Vifor Pharma

* Vifor Pharma to make necessary investments to achieve veltassa’s significant mid-term potential

* Relypsa, Inc., a Vifor Pharma company, has received approval from FDA for a SNDA with important updates to us label of Veltassa (patiromer) for oral suspension Source text - bit.ly/2gxx1jR Further company coverage: (Gdynia Newsroom)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below